Disc Medicine (IRON) Times Interest Earned (2020 - 2026)
Disc Medicine (IRON) posted quarterly Times Interest Earned of -$30.99 for Q2 2026, up 21.79% year-over-year from -$25.44 in Q2 2025, and up 44.11% quarter-over-quarter from -$55.44 in Q1 2026.
Powered by 
Analysis
Disc Medicine (IRON) Times Interest Earned (2020 - 2026) Analysis & Trends
Disc Medicine (IRON) has reported Times Interest Earned for 7 consecutive years, with -$30.99 the latest figure, recorded in Q2 2026.
- In Q2 2026, Times Interest Earned rose 21.79% year-over-year to -$30.99; the TTM figure through Jun 2026 stood at -$128.22 (down 17.77% YoY), while the FY2025 annual figure was -$1.72, down 41.78% from the prior year.
- Times Interest Earned climbed to -$30.99 in Q2 2026 per IRON's latest filing, from -$55.44 in the prior quarter.
- Across five years, Times Interest Earned topped out at -$0.21 in Q2 2023 and bottomed at -$255.59 in Q3 2022.
- Historically, Times Interest Earned has averaged -$64.94 across 5 years, with a median of -$46.69 in 2025.
- Annual changes were most pronounced in 2023 — Times Interest Earned soared 99.91% — and 2025, when it tumbled 8711.18%.
- Disc Medicine's Times Interest Earned stood at -$163.27 in 2022, then jumped by 99.87% to -$0.22 in 2023, then slumped by 27361.32% to -$60.4 in 2024, then dropped by 26.57% to -$76.45 in 2025, then surged by 59.47% to -$30.99 in 2026.
- Business Quant data shows IRON's Times Interest Earned at -$30.99 in Q2 2026, -$55.44 in Q1 2026, and -$76.45 in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.77 Bn | 130.92 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.51 Bn | 77.52 Bn | 3.93 Bn | 117.59 |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | -493.00 |
| 4 | Moderna | 58.20 Bn | 53.06 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | -21.24 |
| 6 | BeOne Medicines | 39.99 Bn | 34.89 Bn | 1.53 Bn | 8.18 |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | 2.82 |
| 8 | Royalty Pharma | 28.40 Bn | 27.56 Bn | - | 1.42 |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | -0.08 |
| 10 | Disc Medicine | 3.09 Bn | 3.09 Bn | - | -71.67 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -71.67 |
| Mar 31, 2026 | -82.37 |
| Dec 31, 2025 | -75.84 |
| Sep 30, 2025 | -73.82 |
| Jun 30, 2025 | -67.48 |
| Mar 31, 2025 | -44.53 |
| Dec 31, 2024 | -60.40 |
| Sep 30, 2022 | -255.59 |
| Jun 30, 2022 | -250.31 |
| Mar 31, 2022 | -150.91 |
| Dec 31, 2021 | 239.14 |
| Sep 30, 2021 | -177.40 |
| Jun 30, 2021 | -134.88 |
| Mar 31, 2021 | -8.92 |
| Dec 31, 2020 | -0.18 |
| Sep 30, 2020 | -3.88 |
| Jun 30, 2020 | -62.30 |
| Mar 31, 2020 | -62.95 |